Maintenance medication for opiate addiction: the foundation of recovery
- PMID: 22873183
- PMCID: PMC3411273
- DOI: 10.1080/10550887.2012.694598
Maintenance medication for opiate addiction: the foundation of recovery
Abstract
Illicit use of opiates is the fastest growing substance use problem in the United States, and the main reason for seeking addiction treatment services for illicit drug use throughout the world. It is associated with significant morbidity and mortality related to human immunodeficiency virus, hepatitis C, and overdose. Treatment for opiate addiction requires long-term management. Behavioral interventions alone have extremely poor outcomes, with more than 80% of patients returning to drug use. Similarly poor results are seen with medication-assisted detoxification. This article provides a topical review of the three medications approved by the Food and Drug Administration for long-term treatment of opiate dependence: the opioid-agonist methadone, the partial opioid-agonist buprenorphine, and the opioid-antagonist naltrexone. Basic mechanisms of action and treatment outcomes are described for each medication. Results indicate that maintenance medication provides the best opportunity for patients to achieve recovery from opiate addiction. Extensive literature and systematic reviews show that maintenance treatment with either methadone or buprenorphine is associated with retention in treatment, reduction in illicit opiate use, decreased craving, and improved social function. Oral naltrexone is ineffective in treating opiate addiction, but recent studies using extended-release naltrexone injections have shown promise. Although no direct comparisons between extended-release naltrexone injections and either methadone or buprenorphine exist, indirect comparison of retention shows inferior outcome compared with methadone and buprenorphine. Further work is needed to directly compare each medication and determine individual factors that can assist in medication selection. Until such time, selection of medication should be based on informed choice following a discussion of outcomes, risks, and benefits of each medication.
Similar articles
-
Adjunctive memantine for opioid use disorder treatment: A systematic review.J Subst Abuse Treat. 2019 Dec;107:38-43. doi: 10.1016/j.jsat.2019.10.003. Epub 2019 Oct 20. J Subst Abuse Treat. 2019. PMID: 31757263
-
Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.Curr Drug Abuse Rev. 2012 Mar;5(1):52-63. doi: 10.2174/1874473711205010052. Curr Drug Abuse Rev. 2012. PMID: 22280332 Free PMC article. Review.
-
Use of naltrexone in treating opioid use disorder in pregnancy.Am J Obstet Gynecol. 2020 Jan;222(1):83.e1-83.e8. doi: 10.1016/j.ajog.2019.07.037. Epub 2019 Jul 31. Am J Obstet Gynecol. 2020. PMID: 31376396
-
Medications for management of opioid use disorder.Am J Health Syst Pharm. 2019 Jul 18;76(15):1097-1103. doi: 10.1093/ajhp/zxz105. Am J Health Syst Pharm. 2019. PMID: 31361869 Review.
-
Heroin anticraving medications: a systematic review.Am J Drug Alcohol Abuse. 2010 Nov;36(6):332-41. doi: 10.3109/00952990.2010.505991. Epub 2010 Oct 19. Am J Drug Alcohol Abuse. 2010. PMID: 20955107 Review.
Cited by
-
Change in substance use among patients in opioid maintenance treatment: baseline to 1-year follow-up.Harm Reduct J. 2024 May 24;21(1):101. doi: 10.1186/s12954-024-01005-x. Harm Reduct J. 2024. PMID: 38790008 Free PMC article.
-
Retention of people who inject drugs enrolled in a 'medications for opioid use disorder' (MOUD) programme in Uganda.Addict Sci Clin Pract. 2024 May 15;19(1):39. doi: 10.1186/s13722-024-00468-4. Addict Sci Clin Pract. 2024. PMID: 38750568 Free PMC article.
-
Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders.Psychopharmacology (Berl). 2024 Jul;241(7):1477-1490. doi: 10.1007/s00213-024-06578-w. Epub 2024 May 6. Psychopharmacology (Berl). 2024. PMID: 38710856 Free PMC article.
-
Identifying the Heterogeneity in the Association between Workforce Diversity and Retention in Opioid Treatment among Black clients.Res Sq [Preprint]. 2024 Feb 8:rs.3.rs-3932153. doi: 10.21203/rs.3.rs-3932153/v1. Res Sq. 2024. PMID: 38405811 Free PMC article. Preprint.
-
Canadian Addiction Treatment Centre (CATC) opioid agonist treatment cohort in Ontario, Canada.BMJ Open. 2024 Feb 24;14(2):e080790. doi: 10.1136/bmjopen-2023-080790. BMJ Open. 2024. PMID: 38401902 Free PMC article.
References
-
- Degenhardt L, Bucello C, Calabria B, et al. What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. Drug and Alcohol Dependence. 2011;117:85–101. - PubMed
-
- World Health Organization. Geneva: WHO Press; 2009. Global health risks: mortality and burden of disease attributable to selected major risks.
-
- Salomon N, Perlman DC, Friedmann P, Ziluck V, Des J. Prevalence and risk factors for positive tuberculin skin tests among active drug users at a syringe exchange program. Int J Tuberc Lung Dis. 2000;4:47–54. - PubMed
-
- Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. The Lancet. 2008;372:1733–1745. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical